|
NHLRC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.23308047001092E-12 |
| Normal-vs-Stage3 |
3.44169137633799E-15 |
| Normal-vs-Stage4 |
3.70647956771109E-12 |
| Stage1-vs-Stage2 |
1.667030E-01 |
| Stage1-vs-Stage3 |
2.905000E-01 |
| Stage1-vs-Stage4 |
1.937610E-01 |
| Stage2-vs-Stage3 |
5.905200E-01 |
| Stage2-vs-Stage4 |
9.241200E-01 |
| Stage3-vs-Stage4 |
6.578200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.24329999999929E-05 |
| Normal-vs-Asian |
2.09059991540528E-10 |
| Caucasian-vs-AfricanAmerican |
1.701570E-01 |
| Caucasian-vs-Asian |
9.059800E-01 |
| AfricanAmerican-vs-Asian |
3.084600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.77475828372553E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.120800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
3.33066907387547E-16 |
| Normal-vs-Age(61-80Yrs) |
1.63724589441472E-12 |
| Normal-vs-Age(81-100Yrs) |
3.97130000000523E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.024800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.574800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.493600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.580400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.308800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.509200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.661000E-01 |
| Classical-VS-Follicular |
3.364200E-01 |
| Classical-VS-Other |
4.262400E-01 |
| Classical-VS-Normal |
9.3137719758829E-12 |
| Tall-VS-Follicular |
8.342400E-01 |
| Tall-VS-Other |
5.208200E-01 |
| Tall-VS-Normal |
7.57879980994858E-10 |
| Follicular-VS-Other |
6.943000E-01 |
| Follicular-VS-Normal |
3.85691478754779E-12 |
| Other-VS-Normal |
2.598800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
5.9986016154312E-11 |
| N0-vs-N1 |
9.882600E-01 |
|
|
